Karboplatin Accord

Carboplatin, the active ingredient in Karboplatin Accord, is a platinum compound presented as an injection solution for intravenous use. It is employed in the treatment of several solid tumours, including ovarian, lung, cervical and head and neck cancers, primarily in adult oncology patients and is administered under medical supervision.

GNH USA supplies Karboplatin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring consistent quality and regulatory compliance across global markets through established distribution channels.

Carboplatin is a platinum‑based chemotherapy agent used in the treatment of solid tumours.

- Ovarian cancer: improves progression‑free survival in advanced disease. - Lung cancer: used in combination regimens for non‑small cell lung carcinoma. - Cervical cancer: employed as part of concurrent chemoradiotherapy for locally advanced disease. - Head and neck cancer: used with radiation to enhance tumour control.

Common Side Effects: - Nausea and vomiting - Fatigue - Decreased blood cell counts (anemia, neutropenia, thrombocytopenia) - Electrolyte disturbances (e.g., low magnesium)

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis) - Kidney (renal) toxicity - Severe bone marrow suppression leading to infection - Pulmonary toxicity (interstitial pneumonitis)

Before initiating therapy, consider the following precautions: - Renal impairment: adjust dose based on creatinine clearance. - Hematologic monitoring: perform regular complete blood counts. - Auditory function: assess hearing, especially with high cumulative doses. - Hypersensitivity: avoid in patients with known allergy to platinum compounds. - Hydration: ensure adequate fluid intake before and after infusion. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Carboplatin may interact with other medicines. Review the following:

Major Interactions (Avoid): - Concurrent use with other platinum‑based chemotherapies (e.g., cisplatin) increases toxicity. - Co‑administration with nephrotoxic drugs such as aminoglycosides can worsen renal impairment. - Combination with high‑dose radiation therapy may heighten tissue damage.

Moderate Interactions (Monitor Closely): - NSAIDs or ACE inhibitors may affect renal clearance; monitor kidney function. - Concomitant myelosuppressive agents can exacerbate blood‑cell suppression; adjust dosing as needed.